When was Beacon Biosignals founded?

Beacon Biosignals was founded in 2019 and raised its 1st funding round 2 years after it was founded.

Where is Beacon Biosignals located?

Beacon Biosignals is headquartered in Boston, United States.

Who is the current CEO of Beacon Biosignals?

Jacob Donoghue of Beacon Biosignals. They have also founded 1 company.

How many employees does Beacon Biosignals have?

As of Aug 31, 2026, the latest employee count at Beacon Biosignals is 180.

Is Beacon Biosignals a funded company?

Beacon Biosignals is a funded company, having raised a total of $141M across 3 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Nov 08, 2021.

When was the latest funding round of Beacon Biosignals?

Beacon Biosignals' latest funding was a $***** Series B round on Apr 06, 2026, with participation from 3 investors.

Where does Beacon Biosignals rank among its competitors?

Beacon Biosignals ranks 3rd amongst 138 active competitors, of which 56 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was Neurosoft Bioelectronics, which secured $7.5M in May, 2026.

Who are the top competitors of Beacon Biosignals?

Beacon Biosignals' top competitors include Ceribell, Empatica and BrainCo. Among them, Neurosoft Bioelectronics secured the most recent funding round in May, 2026.

Beacon Biosignals - 2026 Company Profile, Team, Funding & Competitors

Beacon Biosignals is a series B company based in Boston (United States), founded in 2019 by Sydney Cash, Jacob Donoghue and Quentin Soulet. It operates as an AI-based EEG analysis and diagnosis platform for healthcare providers. Beacon Biosignals has raised $141M in funding from General Catalyst. The company has 138 active competitors, including 56 funded and 5 that have exited. Its top competitors include companies like Ceribell, Empatica and BrainCo.

Company Details

AI-based EEG analysis and diagnosis platform for healthcare providers. The company has devised an EED diagnosis platform that assists professionals with the study of neurological and psychiatric diseases. The platform has the ability to capture real-time brain activity. The data enables professionals to quantify treatment plans, identify the optimal patient population, and more.

Website: beacon.bio
Social
Email ID: *****@beacon.bio

Key Metrics

Founded Year

2019

Location

Boston, United States

Stage

Series B

Total Funding

$141M in 3 rounds

Latest Funding Round

Series B, Apr 06, 2026, $*****

Investors

General Catalyst & 12 more

Ranked

3^rd among 138 active competitors

Employee Count

180 as on Aug 31, 2026

Investment & Acquisitions

Dreem

Similar Companies

Ceribell & 142 more

View Beacon Biosignals' full profile

Beacon Biosignals is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
BEACON BIOSIGNALS, INC. CIN: 833040121 , United States, Active	Dec 31, 1999	-	47 (As on Dec 31, 2024)	-

Beacon Biosignals has raised a total funding of $141M over 3 rounds. Its first funding round was on Nov 08, 2021. Its latest funding round was a Series B round on Apr 06, 2026 for $*****. 3 investors participated in its latest round. Beacon Biosignals has 12 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of Beacon Biosignals:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 06, 2026	3868077	Series B	9766849	4153002	5246170	4119171
Oct 07, 2025	5772462	Series B	8833875	4165790	8078437	Innoviva & 7 more
Nov 08, 2021	1330036	Series A	5950438	3995708	General Catalyst	Casdin Capital & 1 more

Access funding benchmarks and valuations. Sign up today!

View details of Beacon Biosignals's funding rounds and investors

The founders of Beacon Biosignals are Sydney Cash, Jacob Donoghue and Quentin Soulet. Jacob Donoghue is the CEO of Beacon Biosignals.

Here are the details of Beacon Biosignals' key team members:

Sydney Cash: Co-Founder of Beacon Biosignals.
Contact Info: 1 email address
Jacob Donoghue: Co-Founder & CEO of Beacon Biosignals.
Contact Info: 1 email address
Quentin Soulet: Co-Founder & CTO of Beacon Biosignals and founder of 1 other company.

Beacon Biosignals' Board of Directors

Beacon Biosignals's board has 3 active members. Naveen Rao, Jarrett Revels and Jacob A. Donoghue are independent board members.

Here is the list of Beacon Biosignals' board of directors:

Name	Type	Representing	Status	Duration
Naveen Rao	Independent board member	-	Current	7y 5m
rnewpef	Independent board member	-	Current	4y 4m
{adimvd	Independent board member	-	Current	2y 5m

View details of Beacon Biosignals's Founder profiles and Board Members

Beacon Biosignals' employee count trend

Beacon Biosignals has 180 employees as of Aug 26. Here is Beacon Biosignals's employee count trend over the years:

Employee count trend for Beacon Biosignals

Uncover Beacon Biosignals' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Beacon Biosignals include Ceribell, Empatica and BrainCo. Here is the list of Top 10 competitors of Beacon Biosignals, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Ceribell 2014, Mountain View (United States), Public	EEG system for the diagnosis of seizures	$188M	The Rise Fund, Longitude Capital & 11 others	69/100
2nd	Empatica 2011, Milano (Italy), Series B	Developer of a wrist band to monitor physiological signals	$30.9M	RA Capital Management, Sanofi Ventures & 5 others	66/100
3rd	Beacon Biosignals 2019, Boston (United States), Series B	AI-based EEG analysis and diagnosis platform for healthcare providers	$141M	Google Ventures, Logos & 11 others	63/100
4th	BrainCo 2015, Somerville (United States), Series A	Provider of a prosthetic hand and EEG headband for brain signal	$292M	IDG Capital, Walden International & 10 others	58/100
5th	BrainScope 2006, Bethesda (United States), Series B	Provider of AI-powered non-invasive medical devices for diagnosing and assessing brain injuries, including concussions and brain bleeds	$62.2M	Maryland Venture Fund, Aon & 11 others	58/100
6th	Spark Biomedical 2018, Houston (United States), Series A	Developer of wearable neurostimulation technology for drug-free opioid withdrawal treatment	$31.2M	Wave Ventures, Wellcome Leap & 5 others	56/100
7th	Emotiv 2011, San Francisco (United States), Seed	Manufacturer of wireless EEG headsets and software solutions	$7.41M	Disney Accelerator, The Wells Investment & 3 others	56/100
8th	Cortical Labs 2019, Melbourne (Australia), Series A	Manufacturer of AI-powered biochips	$11.6M	Horizons Ventures, January Capital & 9 others	55/100
9th	Neurosoft Bioelectronics 2019, Geneva (Switzerland), Seed	Provider of soft implantable electrodes for neurological disorders	$20M	Fongit, IAG Capital Partners & 6 others	55/100
10th	Cercare Medical 2013, Aarhus (Denmark), Series A	Provider of diagnostic software for acute stroke management	$7.82M	West Hill Capital, Philips HealthWorks & 4 others	55/100